- Report
- February 2025
- 144 Pages
Global
From €2717EUR$2,999USD£2,342GBP
- Report
- April 2025
- 189 Pages
Global
From €3465EUR$3,825USD£2,987GBP
€4077EUR$4,500USD£3,514GBP
- Report
- February 2025
- 182 Pages
Global
From €3465EUR$3,825USD£2,987GBP
€4077EUR$4,500USD£3,514GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1812EUR$2,000USD£1,562GBP
- Report
- April 2025
- 200 Pages
Global
From €7202EUR$7,950USD£6,208GBP
- Report
- April 2025
- 200 Pages
Global
From €7202EUR$7,950USD£6,208GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1359EUR$1,500USD£1,171GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1359EUR$1,500USD£1,171GBP
- Drug Pipelines
- April 2025
- 40 Pages
Global
From €1132EUR$1,250USD£976GBP
- Report
- November 2024
- 97 Pages
Global
From €7202EUR$7,950USD£6,208GBP
- Report
- October 2024
- 160 Pages
Global
From €7202EUR$7,950USD£6,208GBP
- Report
- October 2024
- 207 Pages
Global
From €7202EUR$7,950USD£6,208GBP
- Report
- June 2025
- 150 Pages
Global
From €2445EUR$2,699USD£2,107GBP
- Report
- June 2025
- 150 Pages
Global
From €2445EUR$2,699USD£2,107GBP
- Report
- June 2025
- 200 Pages
Global
From €2527EUR$2,789USD£2,178GBP
- Report
- June 2025
- 200 Pages
Global
From €2527EUR$2,789USD£2,178GBP
- Report
- June 2025
- 200 Pages
Global
From €2527EUR$2,789USD£2,178GBP
- Report
- August 2024
- 200 Pages
Global
From €4483EUR$4,949USD£3,864GBP
- Report
- March 2025
- 255 Pages
Global
From €2265EUR$2,500USD£1,952GBP
- Report
- June 2025
- 85 Pages
Global
From €9054EUR$9,995USD£7,804GBP

Rituximab is a monoclonal antibody used to treat a variety of immune disorders, including rheumatoid arthritis, systemic lupus erythematosus, and non-Hodgkin's lymphoma. It works by targeting and destroying B-cells, which are a type of white blood cell involved in the body's immune response. Rituximab is administered intravenously and is often used in combination with other drugs.
Rituximab is a relatively new drug, having been approved by the US Food and Drug Administration in 1997. Since then, it has become a popular treatment for immune disorders, due to its effectiveness and relatively low side effects. It is also used off-label to treat a variety of other conditions, such as multiple sclerosis and vasculitis.
The market for rituximab is highly competitive, with several major pharmaceutical companies producing the drug. These include Roche, Merck, Pfizer, and Biogen. Additionally, there are several generic versions of the drug available, produced by companies such as Sandoz and Teva Pharmaceuticals. Show Less Read more